{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T10:00:18Z","timestamp":1783850418797,"version":"3.55.0"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT02292719"],"award-info":[{"award-number":["NCT02292719"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2018,2]]},"abstract":"Summary<\/jats:title>The efficacy and safety of an investigational combination of ombitasvir\/paritaprevir\/ritonavir (OBV<\/jats:styled-content>\/PTV<\/jats:styled-content>\/r) plus sofosbuvir (SOF<\/jats:styled-content>) \u00b1 ribavirin (RBV<\/jats:styled-content>) in patients with HCV<\/jats:styled-content> genotype 2 or 3 infection with or without cirrhosis was evaluated. Patients with HCV<\/jats:styled-content> genotype 3 infection without cirrhosis were randomized to receive OBV<\/jats:styled-content>\/PTV<\/jats:styled-content>\/r + SOF<\/jats:styled-content> \u00b1 RBV<\/jats:styled-content> for 12\u00a0weeks; OBV<\/jats:styled-content>\/PTV<\/jats:styled-content>\/r + SOF<\/jats:styled-content> + RBV<\/jats:styled-content> was administered to genotype 3\u2010infected patients with cirrhosis for 12\u00a0weeks and to genotype 2\u2010infected patients without cirrhosis for either 6 or 8\u00a0weeks. Efficacy was assessed by sustained virologic response [HCV RNA<\/jats:styled-content> <25 IU<\/jats:styled-content>\/mL<\/jats:styled-content>] 12\u00a0weeks post\u2010treatment (SVR<\/jats:styled-content>12). Safety was assessed in all treated patients. In patients with genotype 3 infection with or without cirrhosis treated with 12\u00a0weeks of OBV<\/jats:styled-content>\/PTV<\/jats:styled-content>\/r + SOF<\/jats:styled-content> \u00b1 RBV<\/jats:styled-content>, the overall SVR<\/jats:styled-content>12 rate was 98% (50\/51), with no virologic failures. Patients with genotype 2 infection treated with OBV<\/jats:styled-content>\/PTV<\/jats:styled-content>\/r + SOF<\/jats:styled-content> + RBV<\/jats:styled-content> had SVR<\/jats:styled-content>12 rates of 90% (9\/10) and 44% (4\/9) following 8\u2010 and 6\u2010week treatment durations, respectively; failure to achieve SVR<\/jats:styled-content>12 for these patients was due to relapse without baseline or treatment\u2010emergent resistance\u2010associated substitutions. Thus, the investigational combination of OBV<\/jats:styled-content>\/PTV<\/jats:styled-content>\/r with SOF<\/jats:styled-content> \u00b1 RBV<\/jats:styled-content> was well tolerated and achieved high SVR<\/jats:styled-content> rates with no virologic failures in patients with genotype 3 infection. Combining direct\u2010acting antivirals with complementary mechanisms of action and different viral targets may be an effective treatment strategy that may allow for shorter durations of therapy.<\/jats:p>","DOI":"10.1111\/jvh.12782","type":"journal-article","created":{"date-parts":[[2017,8,20]],"date-time":"2017-08-20T09:46:37Z","timestamp":1503222397000},"page":"118-125","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety results of patients with HCV<\/scp> genotype 2 or 3 infection treated with ombitasvir\/paritaprevir\/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II<\/scp>\u2010III<\/scp>)"],"prefix":"10.1111","volume":"25","author":[{"given":"S. D.","family":"Shafran","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine University of Alberta Hospital Edmonton AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Royal Adelaide Hospital Adelaide SA Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Charafeddine","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies Kings College Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. R.","family":"Foster","sequence":"additional","affiliation":[{"name":"Queen Mary University of London Barts Health London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Abunimeh","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pilot\u2010Matias","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. K.","family":"Pothacamury","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Fu","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cohen","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. E.","family":"Cohen","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gane","sequence":"additional","affiliation":[{"name":"Liver Unit Auckland City Hospital Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"issue":"1","key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower E","year":"2014","journal-title":"J Hepatol"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01481.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.05.016"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27095"},{"key":"e_1_2_8_7_1","unstructured":"Gilead Sciences.SOVALDI (sofosbuvir) tablets for oral use [package insert]."},{"key":"e_1_2_8_8_1","unstructured":"Bristol\u2010Myers Squibb.DAKLINZA (daclatasvir) tablets for oral use [package insert]."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13206"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw387"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13383"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312444"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12708"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12611"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.011"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"e_1_2_8_17_1","first-page":"153","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","author":"European Association for the Study of the Liver","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2147\/PPA.S30339","article-title":"Patient adherence issues in the treatment of hepatitis C","volume":"8","author":"Larrey D","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04226-14"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04227-14"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.09.008"},{"key":"e_1_2_8_22_1","unstructured":"Sofosbuvir NDA 204671\/S000.US Food and Drug Administration Division of Antiviral Products;2013."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01913-15"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"S1061","DOI":"10.1016\/S0016-5085(17)33584-9","article-title":"Elbasvir\/grazoprevir plus sofosbuvir in treatment\u2010naive and treatment\u2010experienced cirrhotic patients with hepatitis C virus genotype 3 infection treated for 8, 12 or 16 weeks: final results of the C\u2010ISLE study","volume":"152","author":"Haber B","year":"2017","journal-title":"Gastroenterology"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.11.007"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61228-9"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28877"},{"key":"e_1_2_8_33_1","doi-asserted-by":"crossref","first-page":"S758","DOI":"10.1016\/S0168-8278(16)01478-1","article-title":"Short duration treatment with sofosbuvir\/velpatasvir plus GS\u20109857 in treatment\u2010naive genotype 1\u20106 HCV\u2010infected patients with or without cirrhosis, Abstract SAT\u2010138","volume":"64","author":"Gane E","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.03.047"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12646"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12782","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/chorus\/v1\/articles\/10.1111%2Fjvh.12782","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T22:12:12Z","timestamp":1695852732000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,14]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/jvh.12782"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12782","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,14]]}}}